| Bioactivity | Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAFG469A with IC50 of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC50 is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence[1]. |
| CAS | 2411851-64-2 |
| Sequence | Thr-Arg-His-Val-Asn-Ile-Leu-Leu-Phe-Met |
| Shortening | TRHVNILLFM |
| Formula | C57H94N16O13S |
| Molar Mass | 1243.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gunderwala AY, et al., Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF. ACS Chem Biol. 2019 Jul 19;14(7):1471-1480. |
Braftide
CAS: 2411851-64-2 F: C57H94N16O13S W: 1243.52
Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the f
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.